Editor’s Note
**Editor’s Note:** Huons Group advances its presence in China with the successful Hutox Launch Symposium in Hangzhou, hosted by local partner IMeik Technology, marking the official debut of its botulinum toxin product in the market.
Huons Group is accelerating its entry into the Chinese market with Hutox, its botulinum toxin product.
Huons Group affiliates Humedix and Huons BioPharma announced on Monday that the “Hutox Launch Symposium” was successfully held last Thursday at the JW Marriott Hotel in Hangzhou, Zhejiang Province, China.
The symposium was hosted by Huons BioPharma’s local Chinese partner, IMeik Technology, and featured Hutox’s official launch in China, as well as an academic exchange program.
Through the symposium, Humedix and Huons BioPharma aimed to expand their engagement with Chinese medical professionals and industry stakeholders while boosting Hutox’s global brand awareness.
During the event, Dr. Chris Gunwoo Kim, Chief Director of Cellinique Clinic, delivered a lecture on Hutox, sharing global trends in botulinum toxin use, practical clinical applications, and administration techniques.
Hutox is a botulinum toxin product indicated for both aesthetic and therapeutic use. It is primarily used to treat glabellar lines and crow’s feet.
In 2022, IMeik secured exclusive import and distribution rights for Huons BioPharma’s botulinum toxin products in Greater China, including Hong Kong and Macau. The company obtained marketing authorization for Hutox from China’s National Medical Products Administration (NMPA) in January.
For the launch event, Humedix leveraged its network of Korean medical professionals to support speaker invitations and streamline academic communications.
— A Huons Group official